Baltimore, MD, February 2, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at BIO CEO & Investor Conference. CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at…
Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling…
Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug…
Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical…
Baltimore, MD, November 11, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” at the Informa Therapeutic…
AGB101 formulation suitable for use in the upcoming HOPE4MCI Phase 3 clinical trial to slow the progression of aMCI, the symptomatic pre-dementia stage of Alzheimer’s disease Baltimore, MD, November 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for…
Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the…
BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at…
Public-private partnership will support first and only trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD, September 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today…
First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease Restored brain function to pre-disease levels and significantly improved memory BALTIMORE, MD March 11, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing…
